Virpax files provisional patent application for intranasal delivery

Virpax announced that it has filed a new provisional patent application with the United States Patent and Trademark Office USPTO entitled “Intranasal Delivery” related to its Envelta product candidate. Envelta utilizes Molecular Envelope Technology for the delivery of Enkephalin intranasally for severe cancer pain and non-cancer pain. The enkephalin/MET formulation is delivered using a delivery device which propels the formulation into nose such that the enkephalin is delivered to the brain. MET was developed by Nanomerics Ltd., a UK-based nanotechnology research and development company. Nanomerics has licensed its technology to Virpax, which is utilizing the nose-to-brain MET platform to enhance drug delivery for certain of its product candidates including Envelta. The development program for Envelta is being funded almost exclusively through a Cooperative Research and Development Agreement with the National Center for Advancing Translational Sciences part of the National Institute of Health.